<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68723">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788540</url>
  </required_header>
  <id_info>
    <org_study_id>12013</org_study_id>
    <nct_id>NCT01788540</nct_id>
  </id_info>
  <brief_title>Single Dose Intralipid for Recurrent Unexplained Miscarriage</brief_title>
  <official_title>The Role of Single Dose Intralipid in Cases of Recurrent Unexplained Miscarriage Undergoing IVF / ICSI Cycles, a Prospective Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's Health University Hospital, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Woman's Health University Hospital, Egypt</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intralipid infusion can improve the outcome in women with recurrent Unexplained miscarriages
      undergoing IVF/ICSI cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infertile patients undergoing Intracytoplasmic Sperm Injection (ICSI) cycle with history of
      recurrent unexplained miscarriages, intralipid will be given to the intervention group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>chemical pregnancy rate</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive pregnancy test in blood as measured by quantitative B- hCG level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate,</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Confirmed pregnancy at 7 weeks by ultrasound visualization of gestational sac and positive fetal pulsations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>clinical pregnancy continue after 12 weeks gestational age</description>
  </other_outcome>
  <other_outcome>
    <measure>abortion rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Abortion, Spontaneous</condition>
  <condition>Abortion, Habitual</condition>
  <arm_group>
    <arm_group_label>Intralipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.</description>
    <arm_group_label>Intralipid</arm_group_label>
    <other_name>intralipid 20%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent unexplained miscarriage (3 or more times) in females attempting IVF / ICSI
             cycles

        Exclusion Criteria:

          -  Age above forty years old.

          -  Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies [IgG
             or IgM]); other recognised thrombophilic conditions (testing according to usual
             clinic practice).

          -  Intrauterine abnormalities (as assessed by ultrasound, hysterosonography,
             hysterosalpingogram, or hysteroscopy).

          -  Abnormal parental karyotype.

          -  Other identifiable causes of recurrent miscarriages (tests initiated only if
             clinically indicated) e.g., diabetes, thyroid disease and systemic lupus
             erythematosus (SLE).

          -  Disturbances of normal fat metabolism such as pathologic hyperlipemia

          -  Allergic to it; or to eggs, soybean oil, or safflower oil.

          -  Severe liver disease, kidney disease, lung disease, anemia, blood clotting disorder.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina M Dakhly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine , cairo university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina M Dakhly, M.D.</last_name>
    <phone>01003498919</phone>
    <phone_ext>+2</phone_ext>
    <email>Dinadakhly@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr el ainy hospital</name>
      <address>
        <city>Cairo</city>
        <zip>12211</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina M Dakhly, M.D.</last_name>
      <phone>01003498919</phone>
      <phone_ext>+2</phone_ext>
      <email>Dinadakhly@mail.com</email>
    </contact>
    <investigator>
      <last_name>Dina M Dakhly, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 8, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's Health University Hospital, Egypt</investigator_affiliation>
    <investigator_full_name>Dina Mohamed Refaat Dakhly</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Recurrent miscarriage</keyword>
  <keyword>Implantation failure</keyword>
  <keyword>Intralipid</keyword>
  <keyword>ICSI / IVF failure</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
